investigated the relationship between CPT efficacy and TOP1 activity (including gene and protein levels) in BC cell lines (Luminal, HER2, and TNBC) in vitro, and found that TOP1 activity was not a marker for camptothecin sensitivity in breast cancer (9). This evidence concerns the gene ERBB2 and breast cancer.